NCT03817983View on ClinicalTrials.gov

MRE as a Screening Tool for axSpA in IBD

CompletedOBSERVATIONAL
Enrollment

259

Participants

Timeline

Start Date

March 4, 2019

Primary Completion Date

August 8, 2020

Study Completion Date

August 8, 2020

Conditions
Axial SpondyloarthritisCrohn Disease
Interventions
DIAGNOSTIC_TEST

MRE review for evidence of axSpA in SIJs

Screening for evidence of axSpA on the MRE scan of patients with Crohn's disease

DIAGNOSTIC_TEST

Clinical assessment and dedicated MRI of the spine and pelvis

Clinical assessment and dedicated MRI of the spine and pelvis to assess for evidence of axSpA

Trial Locations (1)

CB2 0QQ

Rheumatology Research Unit, Cambridge

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Cambridge University Hospitals NHS Foundation Trust

OTHER

NCT03817983 - MRE as a Screening Tool for axSpA in IBD | Biotech Hunter | Biotech Hunter